North American Scientific to Operate as ''NAS Medical''
01 Maggio 2008 - 1:09AM
Business Wire
North American Scientific, Inc. (NASDAQ: NASI) today announced that
effective May 1, 2008, the Company will operate as NAS Medical, a
division of North American Scientific, to reflect the Company�s
focus on its medical therapeutic product opportunities. Although
the Company will not formally change its corporate name, all
product, customer, employee and investor communications will
highlight the new NAS Medical name and logos. Consistent with this
new emphasis, the Company will change its NASDAQ Listing Symbol to
�NASM� from �NASI� effective at the opening of business on May 1,
2008. �Operating under the name NAS Medical more accurately
describes for our customers, employees and shareholders the focus
we have on better therapy for patients with cancer,� said John
Rush, President and CEO. �Our Prospera� brachytherapy seeds for the
treatment of prostate cancer, have been responsible for the
majority of our revenue growth over the last year. Our new
ClearPath� HDR device for the treatment of breast cancer, scheduled
to be released for clinical experience in the coming weeks,
represents additional potential growth and margin improvement.
Market penetration with our medical therapeutic products represent
a sizeable future opportunity and will remain the primary focus of
the Company.� About North American Scientific North American
Scientific is a leader in radiation therapy in the fight against
cancer. Its innovative products provide physicians with tools for
the treatment of various types of cancers. They include Prospera�
brachytherapy seeds and SurTRAK� needles and strands used primarily
in the treatment of prostate cancer. In addition, the Company has
been gaining clinical experience with its first generation
ClearPath� multi-channel catheter breast brachytherapy devices in
2007, and intends to launch the second generation devices in 2008.
They are the only such devices approved for both high dose and
continuous release, or low dose, radiation treatments. The devices
are designed to provide flexible, precise dose conformance and an
innovative delivery system that is intended to offer the more
advanced form of brachytherapy for the treatment of breast cancer.
Please visit www.nasmedical.com for more information. Statements
included in this release that are not historical facts may be
considered forward-looking statements that are subject to a variety
of risks and uncertainties. There are a number of important factors
that could cause actual results to differ materially from those
expressed in any forward-looking statements made by the Company
including, but not limited to, the impact of competitive products
and pricing, technological changes, changes in relationships with
strategic partners and dependence upon strategic partners for the
performance of critical activities under collaborative agreements,
the ability of the Company to successfully directly market and sell
its products, uncertainties relating to patent protection and
regulatory approval, the stable supply of appropriate isotopes,
research and development estimates, market opportunities, risks
associated with strategic opportunities or acquisitions the Company
may pursue and the risk factors included in the Company�s filings
with the Securities and Exchange Commission. Any forward-looking
statements contained in this news release speak only as of the date
of this release, and the Company undertakes no obligation to revise
or update any forward-looking statements, whether as a result of
new information, future results or otherwise.
Grafico Azioni North American Scientific (MM) (NASDAQ:NASM)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni North American Scientific (MM) (NASDAQ:NASM)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a North American Scientific (MM) (NASDAQ): 0 articoli recenti
Più North American Scientific, Inc. Articoli Notizie